AVGO vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Broadcom Inc. and Johnson & Johnson โ fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Broadcom Inc. ยท Technology
$379.86
-41.0% upside to fair value
Grade C
High Quality
VS
Johnson & Johnson ยท Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(-21.7%).
JNJ trades at a lower forward P/E
(29.3x).
These are model outputs โ not personalized investment advice.
See all research โ
Valuation & Fundamentals
| Metric |
AVGO |
JNJ |
| Current Price |
$379.86 |
$253.85 |
| Fair Value Estimate |
$223.93 |
$198.76 |
| Upside to Fair Value |
-41.0%
|
-21.7%
|
| Market Cap |
$1,806.8B |
$611.1B |
| Forward P/E |
61.3x
|
29.3x
|
| EV / EBITDA |
44.1x
|
19.2x
|
| Price / Sales |
23.9x
|
6.3x
|
| Price / FCF |
55.2x
|
34.3x
|
| Revenue Growth YoY |
+47.9%
|
+9.9%
|
| Gross Margin |
67.0%
|
69.1%
|
| Operating Margin |
43.7%
|
26.9%
|
| Return on Equity |
36.4%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.81%
|
2.91%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a business split nearly evenly between these two segments. The company benefits from a durable competitive moat driven by customer concentration in mission-critical infrastructure, high switching costs, and a broad portfolio spanning semiconductors and infrastructure software. Broadcom hโฆ
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,โฆ
Accumulation Zones
| Metric |
AVGO |
JNJ |
| Zone Low |
$167.95 |
$149.07 |
| Zone High |
$190.34 |
$168.95 |
| In Buy Zone? |
No
|
No
|